Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/250525
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals |
Autor: | Lozano-Ojalvo, Daniel CSIC ORCID; Cámara, Carmen; López-Granados, Eduardo; Nozal, Pilar; Pino-Molina, Lucía del; Bravo-Gallego, Luz Yadira; Paz-Artal, Estela; Pion, Marjorie; Correa-Rocha, Rafael; Ortiz, Alberto; López-Hoyos, Marcos; Erro Iribarren, Marta; Portoles, Jose; Rojo-Portoles, María Pilar; Ojeda, Gloria; Cervera, Isabel; González-Pérez, María; Bodega-Mayor, Irene; Montes-Casado, María; Portolés, Pilar; Pérez-Olmeda, Mayte; Oteo, Jesús; Sanchez-Tarjuelo, Rodrigo; Pothula, Venu; Schwarz, Megan; Brahmachary, Manisha; Tan, Anthony Tanoto; Le Bert, Nina; Berin, M. Cecilia; Bertoletti, Antonio; Guccione, Ernesto; Ochando, Jordi | Palabras clave: | COVID-19 T-cell immunity BNT162b2 vaccine SARS-CoV-2 |
Fecha de publicación: | 24-ago-2021 | Editor: | Elsevier BV | Citación: | Cell Reports 36(8): 109570 (2021) | Resumen: | The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals.While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2. | Versión del editor: | https://doi.org/10.1016/j.celrep.2021.109570 | URI: | http://hdl.handle.net/10261/250525 | DOI: | 10.1016/j.celrep.2021.109570 | ISSN: | 2211-1247 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
PIIS2211124721010044.pdf | 1,12 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
71
checked on 23-mar-2024
WEB OF SCIENCETM
Citations
74
checked on 24-feb-2024
Page view(s)
95
checked on 28-mar-2024
Download(s)
227
checked on 28-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons